Bohou Medical Secures Tens of Millions RMB in Series A Funding from Zhongyu Capital and Share Investment to Accelerate Primary Care Network Expansion
According to VCBeat (WeChat ID: vcbeat), Qingdao Bohou Medical, a chain medical service provider focused on primary care, has recently announced the completion of its tens-of-millions-yuan Series A financing round, with Zhongyu Capital and Fenxiang Investment jointly participating in the capital increase.
Among them, the exclusive investor from the Pre-A round shared the investment and continued to increase its stake in this round.Bohou Medical revealed that this round of financing will be used to further strengthen operational capabilities, enhance information-based management and standardized service delivery, explore distinctive value-added diagnostic and treatment models, and accelerate the expansion of its primary care network.
Since its launch of community-based primary healthcare chain services in 2013, Bohou Medical has opened approximately 30 primary care clinics, establishing itself as the market leader in East China and demonstrating leading operational efficiency within the primary healthcare sector.
Founder Yan Honghui holds a Master’s degree in Healthcare Management from the University of Hong Kong. She was among the inaugural cohort of the CEIBS Healthcare Entrepreneurship Program and completed an Executive MBA with a focus on the pharmaceutical sector at Renmin University of China. With over a decade of experience in the pharmaceutical and healthcare services industries, she demonstrates exceptional expertise in operational oversight, talent development, and business expansion.
After more than three years of refining its operational expertise through self-built clinics, Bo Hou is now accelerating its expansion by pursuing both organic growth and acquisitions. Within one year of completing its Pre-A financing round, the number of Bo Hou clinics increased from 8 to approximately 30, expanding its covered population from over 90,000 to more than 300,000 residents. The company has achieved rapid revenue growth while maintaining strong profitability despite significant investment in expansion.
In terms of standardization, informatization, and ecosystem development, BoHou has also achieved critical progress:
Standardization:In July 2017, BoHou Medical Group officially launched its ACHS accreditation process, becoming the first community healthcare institution in mainland China to adopt international top-tier medical service accreditation standards, thereby elevating its standardization and quality to a new level.
Informatics:Proprietary Smart Cloud HIS System Launched, Enabling Full Digitalization of Pharmacy, Billing, Clinical, and Medical Insurance Processes at Clinics. The Next Step Is to Close the Loop Between Doctors and Patients, Fully Digitizing Consultation Workflows, Ensuring Safety in Diagnosis and Treatment, Enhancing Intelligence in Information Systems, and Visualizing Patient Health Data.
Ecosystem Development:Partnered with multiple healthcare service enterprises with distinct specialties in vertical fields to build a more comprehensive healthcare service chain, enabling primary care clinics to access high-end, premium medical services and providing patients with chronic diseases with specialized, vertically integrated treatment plans.
Wang Boyu, Partner at Zhongyu Capital, Participated in This Round of Capital Increase“We are delighted to become an investor in Bohou Medical’s current funding round. The chain operation of primary healthcare is a key focus area for Zhongyu Capital. Through our physician group investment model, we have already established a presence in Sichuan, Hunan, and other regions, covering chain clinics, county-level medical services, and specialized medical institutions at the primary care level. We highly recognize the achievements Bohou Medical has made to date. The company’s refined operational management and its steady, capable team have left a deep impression on us. We look forward to sharing experience and resources with Bohou in the future to accelerate its growth.”
Share Investment demonstrated its confidence in the Bo Hou model and prospects through this additional investment round.Xie Kai, Managing Director of Share Capital Medical Fund, stated, After more than a year of collaboration with the founder, our recognition of their operational expertise, learning agility, and collaborative vision has deepened further. We have also witnessed the solid execution of the expansion plan formulated in the early stages. The company’s development and the industry’s trajectory both serve as positive validations of the investment thesis from the previous round.
Currently, Bo Hou’s revenue model primarily relies on income from its self-operated outpatient clinics and collaborative partnerships. Upon entering the acceleration phase, the company will deeply empower traditional offline clinics through digital management, enhanced operational capabilities, the addition of specialized services, and brand licensing, thereby diversifying its revenue streams.
In 2015, the tiered diagnosis and treatment system was designated as a primary objective for deepening healthcare reform under the “13th Five-Year Plan,” unlocking a RMB 450 billion market in primary care for private institutions. After more than three years of development, numerous “Primary Care+” enterprises and business models have emerged, innovative products serving the primary care population have gained traction, and large pharmaceutical companies have actively sought precise marketing channels targeted at the primary care sector.
VCBeat believes that over the next five years, tiered diagnosis and treatment will remain the central theme of healthcare reform, with broader prospects for primary care. The competitive landscape in key regions—East China, Central China, and South China—has largely taken shape, with major players vying for dominance. The industry has entered the “second half,” characterized by regional consolidation and nationwide expansion. The key competitive focus will be on cross-regional expansion and integration capabilities, underpinned by robust operational performance and sound internal controls.
Yan Honghui stated that ACHS accreditation focuses precisely on the continuous refinement and enhancement of service processes, service details, and service philosophy, providing an optimal authoritative benchmark and external oversight to accelerate the development of BoHou Medical Group and mitigate medical safety risks. This is expected to rapidly establish a differentiated competitive advantage over other community healthcare institutions within a few years.
Regarding development plans, Yan Honghui expressed her hope to “establish more than 100 chain community centers in the future, share our own experience with more primary healthcare institutions, and collaborate with like-minded peers.”
[About Sharing Investment]
FenXiang Investment focuses on early-stage investments in the healthcare and senior living sectors. Its healthcare fund manages assets totaling RMB 1.5 billion and has invested in over 70 projects. Notable portfolio companies include Buchang Pharmaceuticals, Meinian Onehealth Healthcare, BGI Genomics, iCarbonX, Genetron Health, JieNuoFei, Jianyi Technology, Changsen Pharmaceutical, FangEn Medicine, Fiton Biologics, and Dr. Zhang Qiang Medical Group. The core of its investment philosophy is: grounded in cutting-edge advancements, oriented toward the future, and dedicated to discovering innovation.